RANKL
What it means
RANKL is a signal that activates osteoclasts, the cells that break down bone, and it's a key target for some osteoporosis medications.
Understanding RANKL helps explain why inflammation, certain diseases, and specific medications affect how fast your bones break down versus rebuild.
RANKL is a signaling molecule that tells young osteoclast cells to mature and start breaking down bone. It's a normal part of the bone remodeling cycle, where old bone is cleared away and new bone is built in its place. Problems happen when RANKL signaling gets turned up too high, tipping the balance toward more bone breakdown than bone building.
Several things can push RANKL activity higher. Chronic inflammation from conditions like rheumatoid arthritis or inflammatory bowel disease raises RANKL signaling through cytokines such as TNF-alpha, IL-1, and IL-6, which is part of why these conditions are linked to bone loss. Multiple myeloma, a cancer of plasma cells in bone marrow, also releases RANKL along with other factors, aggressively destroying bone while blocking new bone formation at the same time.
Because RANKL plays such a central role, it's also a drug target. Denosumab (brand name Prolia) is a medication that works by blocking RANKL directly, which reduces osteoclast activity and bone breakdown. A key feature of this drug is that its effect stops once dosing stops, so decisions about starting, continuing, or stopping it should always be made with your prescriber.
How sure is this?
Graded Strong Clinical Evidence: Supported by multiple well-designed clinical studies in humans. Read each study with its grade in mind. One study is a piece of the picture, not the whole of it.
Where the Academy teaches it
This page is the short version. The lessons teach it in full, with the context around it and a quiz to lock it in.
Questions people ask about this
Bone medications generally work in one of two ways: they either slow down the cells that break down old bone (antiresorptives), or they actively stimulate the cells that build new bone (anabolics). Which family your drug belongs to tells you a lot about what it can realistically do, and that's worth asking your prescriber about directly.
Read the full answer →Stopping Prolia (denosumab) isn't a neutral event. Because it doesn't build up in your bones the way bisphosphonates do, its protective effect wears off once doses stop. This can lead to a rapid rebound in bone turnover and a risk of multiple vertebral fractures, sometimes within months — so this is a decision to make with your prescriber, not on your own.
Read the full answer →Related words
Osteoclasts are the cells that break down old bone tissue, working alongside bone-building osteoblasts to constantly…
Bone remodeling is the lifelong cycle where cells called osteoclasts remove old bone and osteoblasts build new bone…
Denosumab (Prolia) is a twice-yearly injection that blocks RANKL, a signal osteoclasts need to mature, slowing bone…
Antiresorptive medications, like bisphosphonates and denosumab, slow down the cells that break down old bone,…
Rheumatoid arthritis is an autoimmune disease that causes chronic joint inflammation, and that same inflammation…
Multiple myeloma is a cancer of plasma cells in the bone marrow that disrupts the normal bone rebuilding process,…
Education only, not medical advice. Decisions about tests, medications and treatment belong with your own doctor. OsteoStrong does not diagnose, treat or cure any disease.
